Urinary Molecular Marker Tests in Bladder Cancer: An Overview of Cxbladder

Siamak Daneshmand, MD

Sia Daneshmand, MD, University of Southern California, Los Angeles, CA, gives an overview of hematuria and some of the new urinary molecular marker tests in bladder cancer.

Keywords: hematuria, molecular marker tests, bladder cancer

ABOUT THE AUTHOR

Siamak Daneshmand, MD

Sia Daneshmand, MD, is a Professor of Urology and Medicine (Oncology) with a Clinical Scholar designation at the University of Southern California in Los Angeles. He serves as the Director of Urologic Oncology and the Fellowship Director for the Society of Urologic Oncology (SUO) Fellowship. His primary clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer.

About The Author

Siamak Daneshmand, MD

Sia Daneshmand, MD, is a Professor of Urology and Medicine (Oncology) with a Clinical Scholar designation at the University of Southern California in Los Angeles. He serves as the Director of Urologic Oncology and the Fellowship Director for the Society of Urologic Oncology (SUO) Fellowship. His primary clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. Dr. Daneshmand earned his medical degree from the University of California, Davis. He completed an internship in Surgery with the University of Southern California, Los Angeles, where he also completed his residency in Urology. Dr. Daneshmand subsequently completed a Urological Oncology Fellowship with Keck Hospital of the University of Southern California in Los Angeles. Dr. Daneshmand is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer. He is among the highest-volume surgeons for this disease in the country. His research focuses on optimizing perioperative outcomes following radical cystectomy and post-chemotherapy RPLND, utilizing serum and molecular markers, and integrating new technologies in the diagnosis and management of bladder and testicular cancers. He also investigates functional outcomes following orthotopic urinary diversion. Dr. Daneshmand has served on the American Urological Association (AUA) Guidelines Panels for both non-muscle invasive bladder cancer and testicular cancer. He is the Chair of the Bladder Cancer Section of the SUO Clinical Trials Consortium and a member of the scientific steering committees for several bladder cancer clinical trials. He has led over a dozen clinical trials in bladder cancer, as well as a pivotal investigator-initiated, multi-institutional trial in testicular cancer. He is the President of the Western Section of the AUA and a member of the Alpha Omega Alpha medical honor society. For 15 consecutive years, he has been recognized as one of "America’s Top Cancer Doctors." A career leader in academic research on bladder cancer and germ cell tumors, he also serves as Chair of the SWOG Local Bladder Cancer Committee. Dr. Daneshmand has been a visiting professor at more than 30 institutions worldwide and has presented more than 550 abstracts at scientific meetings. He has authored or co-authored more than 450 peer-reviewed articles, reviews, and book chapters.

Join the GRU Community

Watch, Listen, Learn, and Engage with Experts in the Urology Community.

You have Successfully Subscribed!

Share This